Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Mi7.0
Myo-Inositol – Forschung
Hilft vermutlich
43 begutachtete Studien
Was die Evidenz sagt
Hilft wahrscheinlich
Myo-Inositol scheint in 9 von 11 Studien mit messbaren Effekten zu helfen — die Evidenz tendiert klar ins Positive.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 1995–2026 mit einer typischen Studiengröße von 612 Teilnehmenden.
Basierend auf 43 Studien · 23 Meta-Analysen · 16 RCTs · 43,055 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
9geholfen1unklar1nicht geholfen· 32 weitere ohne bewertete Effektdaten
Nach Outcome
Women's healthUnterstützt einen gesunden Östrogenstoffwechsel und das hormonelle Gleichgewicht · 4-8 weeks · Kann menstruelle Beschwerden und PMS-Symptome lindern · 1-3 cycles
Hilft wahrscheinlich40 Studien
Glucose & metabolicVerbesserte Insulinsensitivität und glykämische Kontrolle · 4-12 weeks · Verbessert die Insulinsignalübertragung, insbesondere bei PCOS und metabolischem Syndrom · 8-12 weeks
Hilft wahrscheinlich35 Studien
Fertility & reproductiveKann die reproduktive Gesundheit und Fruchtbarkeitsmarker unterstützen · 4-12 weeks
Hilft vermutlich11 Studien
Weight management
Überwiegend Mechanismus / Beobachtung6 Studien
Men's vitalityStarke Evidenz für die Normalisierung der Hormone und des Eisprungs bei PCOS · 4-12 weeks
Überwiegend Mechanismus / Beobachtung5 Studien
Anxiety & stressWirksam bei Panikstörung und Zwangsstörung in therapeutischen Dosen · 4-8 weeks
Überwiegend Mechanismus / Beobachtung4 Studien
Skin health
Überwiegend Mechanismus / Beobachtung4 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung4 Studien
Depression & moodVerbesserter Eisprung und hormonelles Gleichgewicht bei PCOS · 3-6 months
Zu wenige bewertete Studien2 Studien
Cholesterol & lipids
Zu wenige bewertete Studien2 Studien
Therapeutic & clinical
Zu wenige bewertete Studien1 Studie
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Sleep & insomniaUnterstützung des Serotonin-Stoffwechselwegs kann das Einschlafen fördern · 2-4 weeks
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 33 Studien mit messbaren Effekten gezogen
Wahrscheinlich echte Effekte
100%
über Studien hinweg
Untersuchte Personen
43k
typische Studie: 612 Personen
Stärkste Designs
39
23 gepoolt, 16 randomisiert
Zeigte Nutzen
82%
9/11 Studien
Wie lange Studien liefen
1–3 Monate
2
Untersuchte Populationen
Women with PCOS6
Women with polycystic ovary syndrome4
Pregnant women3
Women with ovarian aging1
Aktives Forschungsgebiet
31 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
199520102026
1PCOS symptoms improvementMeta-AnalyseCited 2×n=5,501 · very large study2025
Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
Zhao G et al. · Reproductive biology and endocrinology : RB&E (2025)
Inositol significantly decreased total cholesterol and triglyceride levels, while curcumin was most effective in improving low-density and high-density lipoprotein cholesterol levels.
Chromium, inositol, and Omega-3 were found to be beneficial for improving lipid profile.
For improving obesity, sex hormone levels, inflammatory factors and oxidative stress indicators of PCOS patients, carnitine, chromium, and soy isoflavones are effective options, respectively.
2Body weight reductionMeta-AnalyseCited 10×n=2,362 · very large study2023
Carnitine was relatively effective in reducing body mass, while chromium, Omega-3, and selenium were beneficial for improving glucose metabolism.
Hu X et al. · PeerJ (2023)
The network meta-analysis showed that carnitine, inositol, and probiotics reduced body weight and body mass index (BMI) compared to placebo, and carnitine outperformed the other supplements (SUCRAs: 96.04%, 97.73%, respectively).
Omega-3 lowered fasting blood glucose (FBG) (SUCRAs: 93.53%), and chromium reduced fasting insulin (FINS) (SUCRAs: 72.90%); both were superior to placebo in improving insulin resistance index (HOMA-IR), and chromium was more effective than Omega-3 (SUCRAs: 79.99%).
Selenium was potent in raising the quantitative insulin sensitivity index (QUICKI) (SUCRAs: 87.92%).
3Clinical pregnancy ratesMeta-AnalyseCited 25×n=2,617 · very large study2024
The results showed that use of antioxidants not only significantly increased the number of retrieved oocytes and high-quality embryo rates but also reduced the dose of gonadotropin, contributing to...
Shang Y et al. · Advances in nutrition (Bethesda, Md.) (2024)
The results showed that use of antioxidants not only significantly increased the number of retrieved oocytes and high-quality embryo rates but also reduced the dose of gonadotropin, contributing to higher clinical pregnancy rates.
Appropriate antioxidant treatment should be offered at a low dose according to the patient's age and ovarian reserve.
This study was registered at PROSPERO as CRD42022359529.
4Gestational diabetes preventionMeta-AnalyseCited 26×n=1,319 · large study2023
Evidence from seven studies shows that antenatal dietary supplementation with myo-inositol during pregnancy may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy and preterm birth.
Motuhifonua SK et al. · The Cochrane database of systematic reviews (2023)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
For the primary neonatal outcomes, only one study measured the risk of a large-for-gestational-age infant and found myo-inositol was associated with both appreciable benefit and harm (RR 1.40, 95% CI 0.65 to 3.02; 1 study, 234 infants; low-certainty evidence).
Further, myo-inositol may result in little to no difference in caesarean section (RR 0.91, 95% CI 0.77 to 1.07; 4 studies, 829 women; low-certainty evidence).
For the secondary neonatal outcomes, meta-analysis showed no neonatal hypoglycaemia (RR 3.07, 95% CI 0.90 to 10.52; 4 studies; 671 infants; very low-certainty evidence).
5PCOS managementMeta-AnalyseCited 27×n=2,230 · very large study2024
The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive.
Fitz V et al. · The Journal of clinical endocrinology and metabolism (2024)
The evidence supporting the use of inositol in the management of PCOS is limited and inconclusive.
Clinicians and their patients should consider the uncertainty of the evidence together with individual values and preferences when engaging in shared decision-making regarding the use of inositol for PCOS.
6IVF/ICSI outcomes and OHSS reductionMeta-AnalyseCited 4×n=1,827 · large study2024
Metformin and myoinositol may reduce OHSS risk in PCOS patients but did not significantly improve pregnancy outcomes.
Lin L et al. · Journal of ovarian research (2024)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Myoinositol was linked to a shorter gonadotropin duration (SMD = -1.21, 95% CI -2.03 to -0.38) and fewer side effects (OR = 0.23, 95% CI 0.06-0.83) compared to controls.
Metformin led to lower E2 levels, a higher number of mature oocytes, and increased side effects (SMD = -376.52, 95% CI -610.83 to -142.22; SMD = 2.23, 95% CI 0.36-4.10; OR = 6.85, 95% CI 4.32-10.86) than controls.
Metformin and myoinositol may reduce OHSS risk in PCOS patients but did not significantly improve pregnancy outcomes.
7Regular menstrual cycle in PCOSMeta-AnalyseCited 70×n=1,691 · large study2023
Inositol is an effective and safe treatment in PCOS.
Greff D et al. · Reproductive biology and endocrinology : RB&E (2023)
Sehr groß Schaden
← SchlechterKein EffektBesser →
In patients treated with inositols, the risk (CI: 1.13; 2.85) of having a regular menstrual cycle was found by 1.79 higher than in the case of placebo.
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Zhao H et al. · Reproductive health (2021)
Compared with metformin, treatment with myo-inositol + D-chiro-inositol was associated with a greater improvement in menstrual frequency (odds ratio 14.70 [95% confidence interval (CI) 2.31-93.58]).
Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone.
Myo-inositol combined with D-chiro-inositol is particularly efficacious in menstrual recovery.
9Gestational diabetes mellitus incidenceMeta-AnalyseCited 21×n=1,321 · large study2022
In conclusion, 4 g MI nutritional supplementation per day during early pregnancy may reduce GDM incidence and severity, therefore may be a practical and safe approach for the prevention of GDM.
Wei J et al. · Nutrients (2022)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Pooled results were expressed as relative risk (RR) or mean difference (MD) with a 95% confidence interval (95% CI).
Compared with the control group, 4 g myo-inositol (MI) supplementation per day significantly decreased the incidence of GDM (RR = 0.30, 95% CI (0.18, 0.49), p < 0.00001).
It also decreased the need of insulin treatment, and reduced the incidence of preterm delivery and neonatal hypoglycemia.
10Clinical pregnancy rateMeta-AnalyseCited 64×n=6,510 · very large study2017
In this review, there was very low-quality evidence to show that taking an antioxidant may provide benefit for subfertile women, but insufficient evidence to draw any conclusions about adverse events.
Showell MG et al. · The Cochrane database of systematic reviews (2017)
This suggests that among subfertile women with an expected clinical pregnancy rate of 22%, the rate among women using antioxidants would be between 27% and 33%.
Heterogeneity was moderately high.There was insufficient evidence to determine whether there was a difference between the groups in rates of miscarriage (OR 0.79, 95% CI 0.58 to 1.08, P = 0.14, 18 RCTs, 2834 women, I2 = 23%, very low quality evidence).
This suggests that, among subfertile women with an expected miscarriage rate of 7%, use of antioxidants would be expected to result in a miscarriage rate of between 4% and 7%.
11Live birth ratesMeta-AnalyseCited 213×n=4,451 · very large study2017
Our updated review suggests that metformin alone may be beneficial over placebo for live birth, although the evidence quality was low.
Morley LC et al. · The Cochrane database of systematic reviews (2017)
Kein klarer Effekt
← SchlechterKein EffektBesser →
Metformin versus placebo or no treatmentThe evidence suggests that metformin may improve live birth rates compared with placebo (OR 1.59, 95% CI 1.00 to 2.51, 4 studies, 435 women, I2 = 0%, low-quality evidence).
There was no clear evidence of a difference in miscarriage rates (OR 1.08, 95% CI 0.50 to 2.35, 4 studies, 748 women, I2 = 0%, low-quality evidence).
However, the combined therapy group had higher rates of clinical pregnancy (OR 1.59, 95% CI 1.27 to 1.99, 16 studies, 1529 women, I2 = 33%, moderate-quality evidence) and ovulation (OR 1.57, 95% CI 1.28 to 1.92, 21 studies, 1624 women, I2 = 64%, moderate-quality evidence).
12Cycle regularization in PCOSMeta-Analysen=388 · medium study2025
In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy.
Kelly FA et al. · Endocrine (2025)
Differences in acne (p = 0.58), body mass index (p = 0.13), fasting blood glucose (p = 0.07) and HOMA-IR (p = 0.25) were not statistically significant.
In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy.
Further studies are needed to clarify the true benefits of the use of inositol in PCOS treatment.
13Triglyceride levelsMeta-AnalyseCited 10×n=612 · large study2022
Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).
Zhang JQ et al. · European review for medical and pharmacological sciences (2022)
Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs).
Further research warranted to confirm findings
14Hormonal and metabolic parameters in PCOSMeta-AnalyseCited 14×n=460 · medium study2023
Our meta-analysis comparing hormonal and metabolic parameters between MET and MI did not show much significant difference, indicating both drugs are equally beneficial in improving metabolic and hormonal parameters in patients with PCOS.
Fatima K et al. · Irish journal of medical science (2023)
Our meta-analysis comparing hormonal and metabolic parameters between MET and MI did not show much significant difference, indicating both drugs are equally beneficial in improving metabolic and hormonal parameters in patients with PCOS.
15Risk of developing gestational diabetes mellitusMeta-AnalyseCited 25×n=586 · large study2018
Myo-inositol is related to lower incidence of GDM, as well as fasting, 1h, and 2h OGTT value, in pregnant women with high risk of this condition.
Guo X et al. · Journal of diabetes and its complications (2018)
Sehr groß Nutzen
← SchlechterKein EffektBesser →
Likely real
Compared with placebo, patients with myo-inositol supplement had significantly lower the risk of developing GDM (RR=0.44, 95% CI [0.32, 0.62], P<0.0001) without heterogeneity (I2=0%, P=0.99), which was confirmed by TSA.
Myo-inositol did not significantly decrease birth weight (60.60g, 95% CI [-177.21, 56.02], P=0.31) with significant heterogeneity (I2=52%, P=0.12), but was not confirmed by TSA.
Myo-inositol is related to lower incidence of GDM, as well as fasting, 1h, and 2h OGTT value, in pregnant women with high risk of this condition.
16HOMA insulin resistance and estradiol in PCOSMeta-AnalyseCited 37×n=573 · large study2018
Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS.
Zeng L et al. · Endocrine (2018)
Compared with the control group, myoinositol may improve HOMA index (WMD -0.65; 95% CI -1.02, -0.28; P = 0.0005) and increase the E2 level (WMD 16.16; 95% CI 2.01, 30.31; P = 0.03).
There is no enough strong evidence that the myoinositol has an effect on the total testosterone level (WMD -16.11; 95% CI -46.08, 13.86; P = 0.29).
Based on current evidence, myoinositol may be recommended for the treatment of PCOS with insulin resistance, as well as for improving symptoms caused by decreased estrogen in PCOS.
The available evidence is insufficient to recommend nutrient supplementation to improve female infertility in women trying to conceive naturally and those utilising MAR.
Pandey C et al. · Nutrients (2024)
The available evidence is insufficient to recommend nutrient supplementation to improve female infertility in women trying to conceive naturally and those utilising MAR.
However, there is currently no indication that these nutrients pose any risk of significant harm.
19Treatment recommendations for nutraceuticals and phytoceuticals in psychiatric disordersMeta-AnalyseCited 117×2022
Based on the current data and clinician input, a range of nutraceuticals and phytoceuticals were given either a supportive recommendation or a provisional recommendation across a range of various psychiatric disorders.
Sarris J et al. · The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry (2022)
Based on the current data and clinician input, a range of nutraceuticals and phytoceuticals were given either a supportive recommendation or a provisional recommendation across a range of various psychiatric disorders.
However several had only a weak endorsement for potential use; for a few it was not possible to reach a clear recommendation direction, largely due to mixed study findings; while some other agents showed no obvious therapeutic benefit and were clearly not recommended for use.
It is the intention of these guidelines to inform psychiatric/medical, and health professional practice globally.